abs210.txt	purpose		response	to	a	complex	trastuzumab-based	regimen	is	affected	by	multiplefeatures	of	the	tumor	and	its	microenvironment	developing	predictive	algorithmis	key	optimizing	her2-targeting	therapy	experimental	design	we	analyzed	137pretreatment	tumors	with	mrna-seq	dna	exome	sequencing	from	calgb	40601	aneoadjuvant	phase	iii	trial	paclitaxel	plus	trastuzumab	or	withoutlapatinib	in	stage	ii	her2-positive	breast	cancer	adopted	an	elasticnet	regularized	regression	approach	that	controls	for	covarying	features	withinhigh-dimensional	data	first	applied	517	known	gene	expression	signatures	todevelop	elastic	net	model	predict	pcr	which	validated	on	143	samplesfrom	four	independent	trials	next	performed	integrative	analysesincorporating	clinicopathologic	information	somatic	mutation	status	dnacopy	number	alterations	(cna)	results	modelusing	only	predicted	validation	sets	(auc	=	0	76)	analyses	showed	models	containing	clinicalfeatures	were	better	predictors	than	asingle	type	frequently	selected	variables	multiplatform	modelsincluded	amplifications	chromosome	6p	tp53	her2-enriched	subtype	immune	predicting	resistance	included	luminal/er+features	conclusions	using	rna	as	well	integrated	dnamodels	can	improved	accuracy	over	clinical	somaticdna	(mutation	cnas)	molecular	(her2e	luminal)	andthe	(immune	cells)	totrastuzumab	paclitaxel-based	regimens	this	highlights	complexity	ofpredicting	clin	res	1-13	Â©2018aacr
